(Q34115573)

31 July 2017

1 reference

title

Recommendations for rotavirus vaccination: A worldwide perspective (English)

1 reference

31 July 2017

Carlos Rodrigo

1

0 references

Carlo Giaquinto

series ordinal

5

object named as

Carlo Giaquinto

1 reference

31 July 2017

Nuran Salman

2

1 reference

31 July 2017

Vladimir Tatochenko

series ordinal

3

1 reference

31 July 2017

Zsofia Mészner

series ordinal

4

1 reference

31 July 2017

language of work or name

English

0 references

publication date

14 May 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

28

1 reference

31 July 2017

issue

31

1 reference

31 July 2017

page(s)

5100-5108

1 reference

Rotarix (RIX4414): an oral human rotavirus vaccine

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidence-based recommendations for rotavirus vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: Randomised, double-blind, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Effect of Human Rotavirus Vaccine on Severe Diarrhea in African Infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus vaccines and vaccination in Latin America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus and severe childhood diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

The rotavirus vaccine saga

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Burden of rotavirus disease in European Union countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus infection in infants as protection against subsequent infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Cost and cost-effectiveness of childhood vaccination against rotavirus in France

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

The cost-effectiveness of rotavirus vaccination in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Cost-effectiveness and potential impact of rotavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Implementing rotavirus vaccination in Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

[Rotavirus vaccination in France: recommendations of the French Speaking Group of Pediatric Gastroenterology, Hepatology and Nutrition]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

[Immunization schedule of the Spanish Association of Pediatrics: recommendations 2008]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Prevention of rotavirus disease: guidelines for use of rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Vaccination schedule for childhood and adolescence: comparing recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus vaccine introduction in the Americas: progress and lessons learned

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Appendix I: methods for the development of evidence-based recommendations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Physicians' knowledge and attitudes about rotavirus gastroenteritis and rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

How to optimise the coverage rate of infant and adult immunisations in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

How to improve communication on vaccine issues at the national level? INFOVAC-PED: an example from Switzerland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Underimmunization among children: effects of vaccine safety concerns on immunization status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

A survey of pediatricians on the reintroduction of a rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Will pediatricians adopt the new rotavirus vaccine?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

A qualitative assessment of factors influencing acceptance of a new rotavirus vaccine among health care providers and consumers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Intussusception among infants given an oral rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus vaccines: considerations for successful implementation in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Implementation of rotavirus immunization in Philadelphia, Pennsylvania: high levels of vaccine ineligibility and off-label use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

More on RotaShield and intussusception: the role of age at the time of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Improving vaccination programmes in the European Union

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Rotavirus vaccines: targeting the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Failure of live, attenuated oral rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Perinatal risk factors for infant hospitalization with viral gastroenteritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.04.108

10.1016/J.VACCINE.2010.04.108

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference